|
FR2295746A1
(fr)
|
1974-12-23 |
1976-07-23 |
Francaise Coop Pharma |
Nouveaux derives du tryptophane a activite nerveuse centrale renforcee
|
|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
IT1179866B
(it)
|
1984-12-12 |
1987-09-16 |
Rotta Research Lab |
Derivati del triptofano farmaceuticamente attivi e composizioni farmaceutiche che li contengono
|
|
US4576750A
(en)
|
1985-04-22 |
1986-03-18 |
Merck & Co., Inc. |
Tryptophan derivative
|
|
US5157110A
(en)
|
1988-08-20 |
1992-10-20 |
The Government Of The United States Of America |
Synthetic, anti-complement protein
|
|
IL95942A0
(en)
|
1989-10-13 |
1991-07-18 |
Syntex Inc |
Collagen-containing ophthalmic formulation
|
|
US6395888B1
(en)
|
1996-02-01 |
2002-05-28 |
Gilead Sciences, Inc. |
High affinity nucleic acid ligands of complement system proteins
|
|
US6582959B2
(en)
|
1991-03-29 |
2003-06-24 |
Genentech, Inc. |
Antibodies to vascular endothelial cell growth factor
|
|
EP1413587A2
(en)
|
1991-05-03 |
2004-04-28 |
Washington University |
Modified complement system regulator
|
|
US5492135A
(en)
|
1992-09-09 |
1996-02-20 |
Devore; Dale P. |
Collagen modulators for use in photoablation excimer laser keratectomy
|
|
US5482135A
(en)
|
1993-06-29 |
1996-01-09 |
Deere & Company |
Combined hydraulic reservoir and vehicle axle
|
|
WO1995003009A1
(en)
|
1993-07-22 |
1995-02-02 |
Oculex Pharmaceuticals, Inc. |
Method of treatment of macular degeneration
|
|
US5770589A
(en)
|
1993-07-27 |
1998-06-23 |
The University Of Sydney |
Treatment of macular degeneration
|
|
US5470952A
(en)
|
1993-10-20 |
1995-11-28 |
Regeneron Pharmaceuticals, Inc. |
CNTF and IL-6 antagonists
|
|
US5443505A
(en)
|
1993-11-15 |
1995-08-22 |
Oculex Pharmaceuticals, Inc. |
Biocompatible ocular implants
|
|
US5776970A
(en)
|
1994-04-28 |
1998-07-07 |
Yeda Research And Development Co. Ltd. |
Tryptophan derivatives as protein tyrosine kinase blockers and their use in the treatment of neoplastic diseases
|
|
IL117645A
(en)
|
1995-03-30 |
2005-08-31 |
Genentech Inc |
Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
|
|
JPH08280800A
(ja)
|
1995-04-12 |
1996-10-29 |
Nissho Corp |
２液注射用プレフィルドシリンジ
|
|
US5869079A
(en)
|
1995-06-02 |
1999-02-09 |
Oculex Pharmaceuticals, Inc. |
Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
|
|
US6129761A
(en)
|
1995-06-07 |
2000-10-10 |
Reprogenesis, Inc. |
Injectable hydrogel compositions
|
|
US6346398B1
(en)
|
1995-10-26 |
2002-02-12 |
Ribozyme Pharmaceuticals, Inc. |
Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
|
|
US6319897B1
(en)
|
1996-03-13 |
2001-11-20 |
John D. Lambris |
Peptides which inhibit complement activation
|
|
US6299895B1
(en)
|
1997-03-24 |
2001-10-09 |
Neurotech S.A. |
Device and method for treating ophthalmic diseases
|
|
US6503480B1
(en)
|
1997-05-23 |
2003-01-07 |
Massachusetts Institute Of Technology |
Aerodynamically light particles for pulmonary drug delivery
|
|
US6254854B1
(en)
|
1996-05-24 |
2001-07-03 |
The Penn Research Foundation |
Porous particles for deep lung delivery
|
|
US5874064A
(en)
|
1996-05-24 |
1999-02-23 |
Massachusetts Institute Of Technology |
Aerodynamically light particles for pulmonary drug delivery
|
|
WO1997047321A1
(en)
|
1996-06-14 |
1997-12-18 |
The Johns Hopkins University School Of Medicine |
Use of chimeric vaccinia virus complement control proteins to inhibit complement
|
|
JPH1087700A
(ja)
|
1996-06-17 |
1998-04-07 |
Smithkline Beecham Corp |
Ｃ３ａ受容体およびＣ３ａを用いる治療およびスクリーニング方法
|
|
US5797898A
(en)
|
1996-07-02 |
1998-08-25 |
Massachusetts Institute Of Technology |
Microchip drug delivery devices
|
|
US6051698A
(en)
|
1997-06-06 |
2000-04-18 |
Janjic; Nebojsa |
Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
|
|
JP2002503223A
(ja)
|
1997-04-11 |
2002-01-29 |
アドバンスト・メディシン・インコーポレイテッド |
複数の活性分子を供与する分子
|
|
AU6957098A
(en)
|
1997-04-11 |
1998-11-11 |
Advanced Medicine, Inc. |
Polyvalent presenter combinatorial libraries and their uses
|
|
AUPO755097A0
(en)
|
1997-06-25 |
1997-07-17 |
University Of Queensland, The |
Receptor agonist and antagonist
|
|
US6169057B1
(en)
|
1997-09-04 |
2001-01-02 |
The Regents Of The University Of California |
Use of tryptophan and analogs as plant growth regulators
|
|
WO1999013899A1
(en)
|
1997-09-17 |
1999-03-25 |
Trustees Of The University Of Pennsylvania |
Peptides and peptidomimetics for inhibiting complement activation
|
|
US8088386B2
(en)
|
1998-03-20 |
2012-01-03 |
Genentech, Inc. |
Treatment of complement-associated disorders
|
|
JPH11197234A
(ja)
|
1998-01-09 |
1999-07-27 |
Koken Co Ltd |
眼科用コラーゲンゲル成形物
|
|
US7112327B2
(en)
|
1998-02-20 |
2006-09-26 |
Tanox, Inc. |
Inhibition of complement activation
|
|
AU3066699A
(en)
|
1998-03-03 |
1999-09-20 |
Johns Hopkins University, The |
Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation
|
|
AU3485999A
(en)
|
1998-04-10 |
1999-11-01 |
Mayo Foundation For Medical Education And Research |
Neo-tryptophan
|
|
US6197934B1
(en)
|
1998-05-22 |
2001-03-06 |
Collagenesis, Inc. |
Compound delivery using rapidly dissolving collagen film
|
|
US6378526B1
(en)
|
1998-08-03 |
2002-04-30 |
Insite Vision, Incorporated |
Methods of ophthalmic administration
|
|
US7084106B1
(en)
|
1999-01-19 |
2006-08-01 |
University Of Louisville Research Foundation, Inc. |
Application of a viral complement inhibitory protein in the treatment and diagnosis of Alzheimer's Disease
|
|
US6645177B1
(en)
|
1999-02-09 |
2003-11-11 |
Alaris Medical Systems, Inc. |
Directly engaged syringe driver system
|
|
AU3856400A
(en)
|
1999-02-12 |
2000-08-29 |
Collagenesis, Inc. |
Injectable collagen-based system for delivery of cells or therapeutic agents
|
|
US20020102581A1
(en)
|
1999-02-19 |
2002-08-01 |
Hageman Gregory S. |
Diagnostics and therapeutics for ocular disorders
|
|
US7108982B1
(en)
|
1999-02-19 |
2006-09-19 |
University Of Iowa Research Foundation |
Diagnostics and the therapeutics for macular degeneration
|
|
GB9910985D0
(en)
|
1999-05-12 |
1999-07-14 |
Smiths Industries Plc |
Syringe pumps
|
|
HK1045456B
(en)
|
1999-05-25 |
2006-09-08 |
King Faisal Specialist Hospital & Research Centre |
Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection
|
|
IT1307266B1
(it)
|
1999-08-13 |
2001-10-30 |
Cane Srl |
Apparecchio per infusione di farmaci.
|
|
US6331313B1
(en)
|
1999-10-22 |
2001-12-18 |
Oculex Pharmaceticals, Inc. |
Controlled-release biocompatible ocular drug delivery implant devices and methods
|
|
GB9930659D0
(en)
|
1999-12-24 |
2000-02-16 |
Bio Discovery Ltd |
Inhibitors of complement activation
|
|
US20050032733A1
(en)
|
2001-05-18 |
2005-02-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
|
|
US20050020525A1
(en)
|
2002-02-20 |
2005-01-27 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
US7011952B2
(en)
|
2000-02-22 |
2006-03-14 |
University Of Iowa Research Foundation |
Diagnostics and therapeutics for macular degeneration-related disorders
|
|
ES2336887T5
(es)
|
2000-03-30 |
2019-03-06 |
Whitehead Inst Biomedical Res |
Mediadores de interferencia por ARN específicos de secuencias de ARN
|
|
JP4764590B2
(ja)
|
2000-04-29 |
2011-09-07 |
ユニバーシティー オブ アイオワ リサーチ ファウンデーション |
黄班変性関連疾患の診断および治療
|
|
US6692759B1
(en)
|
2000-06-28 |
2004-02-17 |
The Regents Of The University Of California |
Methods for preparing and using implantable substance delivery devices
|
|
WO2002011793A1
(fr)
|
2000-08-08 |
2002-02-14 |
Medical Information Services, Inc. |
Seringue pour preparation de necessaire d'injection, valve coulissante intermediaire pour seringues et preparation de necessaire d'injection
|
|
US7118737B2
(en)
|
2000-09-08 |
2006-10-10 |
Amylin Pharmaceuticals, Inc. |
Polymer-modified synthetic proteins
|
|
EP2896631A1
(en)
|
2000-10-10 |
2015-07-22 |
Genentech, Inc. |
Inhibition of complement C5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
|
|
EP1702635B1
(en)
|
2000-11-09 |
2008-01-16 |
Insulet Corporation |
Transcutaneous delivery means
|
|
CA2429814C
(en)
|
2000-12-01 |
2014-02-18 |
Thomas Tuschl |
Rna interference mediating small rna molecules
|
|
JP2005504715A
(ja)
|
2000-12-29 |
2005-02-17 |
アドバンスト インハレーション リサーチ，インコーポレイテッド |
持続放出特性を有する吸入用粒子
|
|
WO2002055058A2
(en)
|
2001-01-09 |
2002-07-18 |
Microchips, Inc. |
Flexible microchip devices for ophthalmic and other applications
|
|
US7611711B2
(en)
|
2001-01-17 |
2009-11-03 |
Vegenics Limited |
VEGFR-3 inhibitor materials and methods
|
|
US20030175950A1
(en)
|
2001-05-29 |
2003-09-18 |
Mcswiggen James A. |
RNA interference mediated inhibition of HIV gene expression using short interfering RNA
|
|
US20050054596A1
(en)
|
2001-11-30 |
2005-03-10 |
Mcswiggen James |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
|
JP2005511576A
(ja)
|
2001-11-09 |
2005-04-28 |
アイテック・ファーマシューティカルズ |
眼球血管新生病を治療する方法
|
|
EP1453546A2
(en)
|
2001-12-04 |
2004-09-08 |
Nanospectra Biosciences, Inc. |
Treatment of angiogenesis disorders using targeted nanoparticles
|
|
US7261876B2
(en)
|
2002-03-01 |
2007-08-28 |
Bracco International Bv |
Multivalent constructs for therapeutic and diagnostic applications
|
|
AUPS160602A0
(en)
|
2002-04-08 |
2002-05-16 |
University Of Queensland, The |
Therapeutic method
|
|
US7150724B2
(en)
|
2002-06-05 |
2006-12-19 |
Cardinal Health 303, Inc. |
Syringe plunger driver system
|
|
US7018361B2
(en)
|
2002-06-14 |
2006-03-28 |
Baxter International Inc. |
Infusion pump
|
|
AU2003276131A1
(en)
|
2002-06-18 |
2003-12-31 |
Epigenesis Pharmaceuticals, Inc. |
A dry powder oligonucleotide formulation, preparation and its uses
|
|
ITMI20021527A1
(it)
|
2002-07-11 |
2004-01-12 |
Consiglio Nazionale Ricerche |
Anticorpi anti componente c5 del complemento e loro uso
|
|
US7148342B2
(en)
|
2002-07-24 |
2006-12-12 |
The Trustees Of The University Of Pennyslvania |
Compositions and methods for sirna inhibition of angiogenesis
|
|
JP3976635B2
(ja)
|
2002-08-05 |
2007-09-19 |
久光製薬株式会社 |
キット製剤用注射器、注射器型キット製剤用中間摺動弁、及び、注射器型キット製剤、並びにｘ線造影剤キット製剤
|
|
PT1549333E
(pt)
|
2002-09-20 |
2012-01-03 |
Univ Pennsylvania |
Análogos de compstatina com actividade melhorada
|
|
US20060251621A1
(en)
|
2002-09-27 |
2006-11-09 |
Campochiaro Peter A |
Ocular gene therapy
|
|
WO2004037310A2
(en)
|
2002-10-21 |
2004-05-06 |
Allvivo, Inc. |
Surface coating comprising bioactive compound
|
|
WO2004041160A2
(en)
|
2002-10-30 |
2004-05-21 |
University Of Kentucky Research Foundation |
Methods and animal model for analyzing age-related macular degeneration
|
|
US20050048099A1
(en)
|
2003-01-09 |
2005-03-03 |
Allergan, Inc. |
Ocular implant made by a double extrusion process
|
|
WO2004075838A2
(en)
|
2003-02-21 |
2004-09-10 |
Rikshospitalet-Radiumhospitalet Hf |
Method and compositions for the treatment of meconium aspiration syndrome
|
|
US20060140939A1
(en)
|
2003-02-21 |
2006-06-29 |
Fung Sek C M |
Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
|
|
US20050255144A1
(en)
|
2003-04-09 |
2005-11-17 |
Directcontact Llc |
Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
|
|
WO2005023296A1
(en)
|
2003-09-05 |
2005-03-17 |
University Of Louisville Research Foundation, Inc. |
Treatment of rheumatic diseases
|
|
CA2579635A1
(en)
|
2003-09-10 |
2005-03-17 |
Baxter International Inc. |
Peptides that inhibit complement activation
|
|
BRPI0506629A
(pt)
|
2004-02-10 |
2007-05-02 |
Univ Colorado |
inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
|
|
HUE038239T2
(hu)
|
2004-02-12 |
2018-10-29 |
Archemix Llc |
Komplementrendszerrel összefüggõ rendellenességek kezelésében alkalmazható aptamer terapeutikumok
|
|
US20050244469A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Extended therapeutic effect ocular implant treatments
|
|
WO2005110374A1
(en)
|
2004-04-30 |
2005-11-24 |
Allergan, Inc. |
Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
|
|
JP2007537263A
(ja)
|
2004-05-10 |
2007-12-20 |
ノバセア インコーポレイティッド |
活性ビタミンｄ化合物による動脈再狭窄の予防法
|
|
US8840893B2
(en)
|
2004-06-10 |
2014-09-23 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
WO2006080951A2
(en)
|
2004-07-01 |
2006-08-03 |
Yale University |
Targeted and high density drug loaded polymeric materials
|
|
US8043609B2
(en)
|
2004-10-08 |
2011-10-25 |
Potentia Pharmaceuticals, Inc. |
Viral complement control proteins for eye disorders
|
|
WO2006042252A2
(en)
|
2004-10-08 |
2006-04-20 |
Potentia Pharmeceuticals, Inc. |
Viral complement control proteins for eye disorders
|
|
JP2008520242A
(ja)
|
2004-11-18 |
2008-06-19 |
イェール ユニバーシティ |
視覚障害を処置するための方法および組成物
|
|
US7745389B2
(en)
|
2005-02-14 |
2010-06-29 |
University Of Iowa Research Foundation |
Methods for treatment of age-related macular degeneration
|
|
US20060257359A1
(en)
|
2005-02-28 |
2006-11-16 |
Cedric Francois |
Modifying macrophage phenotype for treatment of disease
|
|
EP1861114B1
(en)
|
2005-03-11 |
2011-02-02 |
Potentia Pharmaceuticals, Inc. |
Compositions comprising modulators of g-protein-coupled receptor for treatment of macular degeneration
|
|
US20080097291A1
(en)
|
2006-08-23 |
2008-04-24 |
Hanson Ian B |
Infusion pumps and methods and delivery devices and methods with same
|
|
EP2385061A3
(en)
*
|
2005-05-10 |
2012-02-22 |
Neoloch Aps |
Neuritogenic peptides
|
|
US8168584B2
(en)
|
2005-10-08 |
2012-05-01 |
Potentia Pharmaceuticals, Inc. |
Methods of treating age-related macular degeneration by compstatin and analogs thereof
|
|
EP2662089A3
(en)
|
2005-10-08 |
2014-02-19 |
Potentia Pharmaceuticals, Inc. |
Compstatin and analogs thereof for eye disorders
|
|
US20070134244A1
(en)
|
2005-10-14 |
2007-06-14 |
Alcon, Inc. |
Combination treatment for pathologic ocular angiogenesis
|
|
SG10201804008UA
(en)
|
2005-11-04 |
2018-06-28 |
Genentech Inc |
Use of complement pathway inhibitors to treat ocular diseases
|
|
CN102977191B
(zh)
|
2005-11-28 |
2016-08-10 |
宾夕法尼亚州大学理事会 |
有效的c3补体抑制素类似物
|
|
KR20080087814A
(ko)
|
2005-12-22 |
2008-10-01 |
알콘 리서치, 리미티드 |
보체 인자 ｈ의 위험 변이체가 있는 환자에서 연령 관련황반변성의 예방 및 치료를 위한 ｃ3-전환효소 저해제
|
|
ATE409280T1
(de)
|
2005-12-28 |
2008-10-15 |
Sensile Pat Ag |
Mikropumpe
|
|
US20070196367A1
(en)
|
2006-02-22 |
2007-08-23 |
Valentin Dinu |
Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
|
|
AU2007232206B2
(en)
|
2006-03-30 |
2013-04-04 |
Drais Pharmaceuticals, Inc. |
Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same
|
|
HUE026001T2
(en)
|
2007-02-05 |
2016-04-28 |
Apellis Pharmaceuticals Inc |
Compstatin analogues for use in the treatment of the inflammatory condition of the respiratory system
|
|
EP2134181A4
(en)
|
2007-02-28 |
2011-09-28 |
Serina Therapeutics Inc |
ACTIVATED POLYOXAZOLINES AND COMPOSITION COMPRISING THE SAME
|
|
CA2691002C
(en)
|
2007-07-19 |
2016-05-10 |
Allexcel, Inc. |
Self-assembling amphiphilic polymers as anticancer agents
|
|
WO2009015087A2
(en)
|
2007-07-20 |
2009-01-29 |
Potentia Pharmaceuticals, Inc. |
Compositions and methods for treatment of trauma
|
|
WO2009043027A2
(en)
|
2007-09-27 |
2009-04-02 |
Serina Therapeutics, Inc. |
Multi-armed forms of activated polyoxazoline and methods of synthesis thereof
|
|
BRPI0817524A2
(pt)
|
2007-10-02 |
2017-05-02 |
Potentia Pharmaceuticals Inc |
liberação prolongada de análogos de compstatina provenientes de géis
|
|
BRPI0820535B8
(pt)
|
2007-11-16 |
2021-05-25 |
Novo Nordisk As |
composições farmacêuticas contendo insulina e um peptídeo insulinotrópico
|
|
JP5514736B2
(ja)
|
2008-01-11 |
2014-06-04 |
セリナ・セラピユーテイツクス・インコーポレーテツド |
ポリオキサゾリン共重合体の多機能形態およびそれを含む薬物組成物
|
|
WO2009097468A2
(en)
|
2008-01-29 |
2009-08-06 |
Kliman Gilbert H |
Drug delivery devices, kits and methods therefor
|
|
US20110190221A1
(en)
|
2008-03-28 |
2011-08-04 |
Apellis Ag |
Modulation and repletion/enhancement of the complement system for treatment of trauma
|
|
US8883211B2
(en)
|
2008-07-10 |
2014-11-11 |
Serina Therapeutics, Inc. |
Polyoxazolines with inert terminating groups, polyoxazolines prepared from protected initiating groups and related compounds
|
|
CA2760839C
(en)
|
2009-05-01 |
2019-02-12 |
The Trustees Of The University Of Pennsylvania |
Modified compstatin with peptide backbone and c-terminal modifications
|
|
WO2010135717A2
(en)
|
2009-05-21 |
2010-11-25 |
Potentia Pharmaceuticals, Inc. |
Complement assays and uses thereof
|
|
WO2011005969A2
(en)
|
2009-07-10 |
2011-01-13 |
The General Hospital Corporation |
Etomidate analogues that do not inhibit adrenocortical steroid synthesis
|
|
EP2338520A1
(de)
|
2009-12-21 |
2011-06-29 |
Ludwig Maximilians Universität |
Konjugat mit Zielfindungsligand und dessen Verwendung
|
|
WO2011123659A1
(en)
|
2010-04-01 |
2011-10-06 |
Enable Injections, Llc |
Medical fluid injection device and system
|
|
US8625635B2
(en)
|
2010-04-26 |
2014-01-07 |
Cleversafe, Inc. |
Dispersed storage network frame protocol header
|
|
IT1404942B1
(it)
|
2010-06-11 |
2013-12-09 |
Cane Spa |
Dispositivo per l'infusione simultanea di farmaci in piu' siti di infusione.
|
|
WO2011163394A2
(en)
|
2010-06-22 |
2011-12-29 |
Apellis Pharmaceuticals, Inc. |
Compstatin analogs for treatment of neuropathic pain
|
|
US20130324482A1
(en)
|
2010-07-09 |
2013-12-05 |
Apellis Pharmaceuticals, Inc. |
Compstatin analogs for treatment of rhinosinusitis and nasal polyposis
|
|
CA2813049A1
(en)
|
2010-09-23 |
2012-03-29 |
The Trustees Of The University Of Pennsylvania |
Modified compstatin with improved stability and binding properties
|
|
IT1403780B1
(it)
|
2010-12-02 |
2013-10-31 |
Cane Spa |
Dispositivo per l'infusione di farmaci.
|
|
MX356528B
(es)
|
2011-05-11 |
2018-06-01 |
Apellis Pharmaceuticals Inc |
Analogos de compstatina de celula reactiva, de acción prolongada u objetivos y usos de los mismos.
|
|
EP3524258B1
(en)
|
2011-06-22 |
2025-10-01 |
Apellis Pharmaceuticals, Inc. |
Methods of treating chronic disorders with complement inhibitors
|
|
CA2847862C
(en)
|
2011-09-07 |
2021-01-12 |
The Trustees Of The University Of Pennsylvania |
Compstatin analogs with improved pharmacokinetic properties
|
|
WO2014028861A1
(en)
|
2012-08-17 |
2014-02-20 |
Apellis Pharmaceuticals, Inc. |
Detection of high risk drusen
|
|
US20150217058A1
(en)
|
2012-09-24 |
2015-08-06 |
Enable Injections, Llc |
Medical vial and injector assemblies and methods of use
|
|
WO2014078734A2
(en)
*
|
2012-11-15 |
2014-05-22 |
Apellis Pharmaceuticals, Inc. |
Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
|
|
MX366404B
(es)
*
|
2012-11-15 |
2019-07-08 |
Apellis Pharmaceuticals Inc |
Analogos de compstatina de celula reactiva, de acción prolongada u objetivos y composiciones y metodos relacionados.
|
|
US9512180B2
(en)
|
2012-12-19 |
2016-12-06 |
The Regents Of The University Of California |
Compstatin analogs
|
|
ITMI20122263A1
(it)
*
|
2012-12-28 |
2014-06-29 |
Azienda Ospedaliero Universitaria Di Parma |
Nuovi peptidi cationici ciclici ad attività antimicrobica
|
|
EP2956190A4
(en)
|
2013-02-15 |
2016-08-24 |
Repro Med Systems Inc |
UNIVERSAL MULTI-FLOW TUBUS KIT
|
|
WO2014152391A1
(en)
|
2013-03-15 |
2014-09-25 |
Apellis Pharmaceuticals, Inc. |
Cell-penetrating compstatin analogs and uses thereof
|
|
JP6159886B2
(ja)
|
2013-07-16 |
2017-07-05 |
北京机械▲設▼▲備▼研究所 |
高層及び超高層ビルの消火活動に適用する消防車
|
|
ITTO20130661A1
(it)
|
2013-08-02 |
2015-02-03 |
Cane Spa |
Pompa portatile per l¿infusione di sostanze liquide nel corpo di un essere vivente e serbatoio per l¿uso in detta pompa
|
|
US9806963B2
(en)
|
2013-10-18 |
2017-10-31 |
Cellco Partnership |
Feature activation on device
|
|
NZ631007A
(en)
*
|
2014-03-07 |
2015-10-30 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
|
US10213476B2
(en)
|
2014-03-17 |
2019-02-26 |
The Trustees Of The University Of Pennsylvania |
Compstatin analogs with improved potency and pharmacokinetic properties
|
|
WO2016049385A1
(en)
|
2014-09-24 |
2016-03-31 |
Apellis Pharmaceuticals, Inc. |
Methods and compositions for cancer treatment and treatment selection
|
|
US11903994B2
(en)
*
|
2015-10-07 |
2024-02-20 |
Apellis Pharmaceuticals, Inc. |
Dosing regimens
|
|
JOP20170017B1
(ar)
|
2016-01-25 |
2021-08-17 |
Amgen Res Munich Gmbh |
تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
|
|
RU2019113301A
(ru)
*
|
2016-10-17 |
2020-11-17 |
Апеллис Фармасьютикалс, Инк. |
Комбинированная терапия для ингибирования с3
|
|
IL269844B2
(en)
|
2017-04-07 |
2025-01-01 |
Apellis Pharmaceuticals Inc |
Dosage regimens and related compositions and methods
|
|
WO2019118938A1
(en)
*
|
2017-12-15 |
2019-06-20 |
Apellis Pharmaceuticals, Inc. |
Dosing regimens and related compositions and methods
|
|
WO2021007111A1
(en)
*
|
2019-07-05 |
2021-01-14 |
Apellis Pharmaceuticals, Inc. |
Viral vector therapy
|